SUNNYVALE, Calif., July 26, 2022 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2022. “We achieved several important milestones in the second quarter. We expanded […]
Other News
Family Heart Foundation Study Shows Most Familial Hypercholesterolemia Patients Remain Undiagnosed
Data Highlighted in Poster Presentation at the American Society for Preventive Cardiology Congress on CVD Prevention LOUISVILLE, Ky.–(BUSINESS WIRE)–The Family Heart Foundation, a leading research and advocacy organization, completed an analysis of its large U.S. Family Heart DatabaseTM showing that while the percentage of patients diagnosed with familial hypercholesterolemia (FH) has increased […]
Surmodics Reports Third Quarter Fiscal 2022 Results
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 third quarter ended June 30, 2022 and updated its financial outlook for its fiscal 2022. Summary of Third Quarter and Recent […]
ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise™ System for the Treatment of Hypertension
PALO ALTO, Calif.–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”) and Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings Co., Ltd., today announced that the RADIANCE II US FDA IDE pivotal trial evaluating the Paradise™ Ultrasound Renal Denervation (uRDN) System as a treatment for hypertension met its primary efficacy […]
iRhythm Technologies Announces the Addition of Two Executive Leaders to Advance Strategic Growth and Operational Excellence
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of two seasoned executives to its leadership team. Brice Bobzien will join the company as the Chief Financial Officer on August 8, 2022, […]
First and Only Peripheral Tri-axial 4-French Low-Profile Self-Expanding Stent System Receives FDA Approval
BIOTRONIK Launches its Pulsar-18 T3 Self-Expanding Stent System in the U.S. LAKE OSWEGO, Ore., July 26, 2022 /PRNewswire/ — BIOTRONIK, LAKE OSWEGO, USA, announced that it received U.S. Food and Drug Administration (FDA) approval of its innovative Pulsar®-18 T3 peripheral self-expanding stent system for an improved implantation procedure for endovascular treatments. The company also announced the full U.S. commercial […]
Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer
BOSTON, July 26, 2022 /PRNewswire/ — Elucid, a novel non-invasive software company providing physicians with AI-powered imaging to characterize cardiovascular disease, is pleased to announce that Todd C. Villines, MD, is joining the company as Chief Medical Officer. Dr. Villines will be leading clinical strategy development and execution for Elucid’s commercial and in-development […]
Qardio+ Launches to Add New Level of Convenience to QardioArm Users
The new subscription service takes home health monitoring to the next level. SAN FRANCISCO, July 26, 2022 /PRNewswire/ — Qardio, a leader in connected care with predictive insight for a changing world, announces today the launch of their new subscription service Qardio+. Qardio+ will work with the QardioArm portable blood pressure monitor […]
New Zealand Endovascular Thought Leader Joins the VESTECK Scientific Advisory Board
WEST CHESTER, Pa., July 26, 2022 /PRNewswire/ — VESTECK, Inc. is pleased to announce that, international thought leader, Professor Andrew Holden has graciously agreed to join the VESTECK Scientific Advisory Board (SAB). A New Zealander, Professor Holden is currently the Director of Northern Region Interventional Radiology Service and is based at Auckland City Hospital. […]
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device Exemption (“IDE”) Trial. The approval expands the number of patients eligible for treatment […]



